Tag Archives: ATRA

Top 10 Value Stocks To Buy Right Now

Ontario Teachers Pension Plan Board decreased its stake in Baker Hughes, a GE company (NYSE:BHGE) by 72.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,305 shares of the company’s stock after selling 48,206 shares during the period. Ontario Teachers Pension Plan Board’s holdings in Baker Hughes, a GE were worth $508,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the company. Renaissance Technologies LLC boosted its stake in Baker Hughes, a GE by 1,238.4% during the fourth quarter. Renaissance Technologies LLC now owns 2,124,540 shares of the company’s stock worth $67,220,000 after buying an additional 1,965,800 shares in the last quarter. BlackRock Inc. boosted its stake in Baker Hughes, a GE by 5.5% during the fourth quarter. BlackRock Inc. now owns 30,916,382 shares of the company’s stock worth $978,192,000 after buying an additional 1,618,832 shares in the last quarter. Ceredex Value Advisors LLC acquired a new stake in Baker Hughes, a GE during the first quarter worth $36,831,000. American Century Companies Inc. boosted its stake in Baker Hughes, a GE by 15.2% during the first quarter. American Century Companies Inc. now owns 8,938,740 shares of the company’s stock worth $248,229,000 after buying an additional 1,176,328 shares in the last quarter. Finally, Becker Capital Management Inc. acquired a new stake in Baker Hughes, a GE during the first quarter worth $22,165,000. Institutional investors and hedge funds own 94.77% of the company’s stock.

Top 10 Value Stocks To Buy Right Now: Atara Biotherapeutics, Inc.(ATRA)

Advisors’ Opinion:

  • [By Jason Hall, George Budwell, and Chuck Saletta]

    In order to help you get started, we asked three real-world investors who also write for The Motley Fool to put forth their best “buy now” growth stock ideas, and they came up with high-growth home builderLGI Homes Inc(NASDAQ:LGIH),return-to-growth restaurant chainChipotle Mexican Grill, Inc.(NYSE:CMG), and upstart immunotherapy developerAtara BioTherapeutics Inc(NASDAQ:ATRA).

  • [By Joseph Griffin]

    Rhumbline Advisers boosted its position in shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) by 23.4% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 33,565 shares of the biotechnology company’s stock after purchasing an additional 6,363 shares during the quarter. Rhumbline Advisers’ holdings in Atara Biotherapeutics were worth $1,309,000 at the end of the most recent reporting period.

  • [By Keith Speights]

    There are more small-cap biotech stocks than any investor can realistically keep up with. But three stocks I think you’ll want to keep on your radar areAbeona Therapeutics (NASDAQ:ABEO), Atara Biotherapeutics (NASDAQ:ATRA), and Viking Therapeutics (NASDAQ:VKTX). Here’s why these small-cap biotech stocks are worth monitoring closely.

  • [By Joseph Griffin]

    Atara Biotherapeutics (NASDAQ:ATRA) had its price target decreased by Citigroup from $25.00 to $23.00 in a report released on Monday. Citigroup currently has a sell rating on the biotechnology company’s stock.

  • [By Joseph Griffin]

    Atara Biotherapeutics (NASDAQ:ATRA) Director Matthew K. Fust sold 12,286 shares of Atara Biotherapeutics stock in a transaction dated Monday, May 14th. The stock was sold at an average price of $43.57, for a total value of $535,301.02. Following the completion of the transaction, the director now directly owns 19,820 shares of the company’s stock, valued at approximately $863,557.40. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

  • [By Max Byerly]

    Atara Biotherapeutics (NASDAQ:ATRA) SVP Derrell Porter sold 1,544 shares of the firm’s stock in a transaction on Tuesday, May 8th. The shares were sold at an average price of $40.15, for a total value of $61,991.60. Following the completion of the sale, the senior vice president now owns 12,500 shares in the company, valued at $501,875. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Top 10 Value Stocks To Buy Right Now: Agenus Inc.(AGEN)

Advisors’ Opinion:

  • [By Shane Hupp]

    Shares of Agenus (NASDAQ:AGEN) dropped 9.8% during trading on Monday following a dissappointing earnings announcement. The stock traded as low as $3.30 and last traded at $3.32. Approximately 2,421,286 shares changed hands during mid-day trading, an increase of 53% from the average daily volume of 1,586,724 shares. The stock had previously closed at $3.68.

  • [By Logan Wallace]

    Agenus (NASDAQ:AGEN) was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Monday.

  • [By Cory Renauer]

    Attention bargain shoppers: There could be some deals in aisle biotech.Agenus Inc.(NASDAQ:AGEN)andRegeneron Pharmaceuticals (NASDAQ:REGN) dished out some disappointing losses in recent months, but the market’s reaction to recent events seems a bit overdone.

  • [By Max Byerly]

    Agenus (NASDAQ:AGEN) shares traded up 5.6% during mid-day trading on Thursday . The stock traded as high as $3.44 and last traded at $3.60. 39,070 shares were traded during mid-day trading, a decline of 97% from the average session volume of 1,431,827 shares. The stock had previously closed at $3.41.

  • [By Ethan Ryder]

    Here are some of the news articles that may have effected Accern Sentiment Analysis’s rankings:

    Get Agenus alerts:

    Agenus Inc. (AGEN): Stock Have a Latest Story: (bitcoinpriceupdate.review) P/E and PEG Value Under Consideration Agenus Inc. (NASDAQ:AGEN) (nasdaqjournal.com) Sizzling Spotlight- Kohl’s Corporation (NYSE:KSS), Agenus Inc. (NASDAQ:AGEN), The Hartford Financial Services … (journalfinance.net) Checking on Key Pivot Levels for Agenus Inc. (NASDAQ:AGEN): Woodie Pivot at 3.175 (stocknewscaller.com) Watch List Stock Agenus Inc. (AGEN) (stockmarketstop.com)

    Shares of AGEN traded down $0.10 during trading hours on Friday, reaching $2.70. 6,890,759 shares of the company traded hands, compared to its average volume of 1,149,867. The firm has a market capitalization of $280.80 million, a P/E ratio of -2.20 and a beta of 1.70. Agenus has a 12-month low of $2.70 and a 12-month high of $6.19. The company has a current ratio of 2.16, a quick ratio of 2.16 and a debt-to-equity ratio of -0.11.

  • [By Cory Renauer]

    Harnessing the power of the immune system to fight cancer is a big deal and Agenus Inc. (NASDAQ:AGEN) looks like a great way to follow the trend. This stock trades like a small-cap biotech, but a couple of candidates coming through its pipeline could help push annual revenue past the $1 billion mark. Plus, by this time next year, the company could have half a dozen or so new candidates in clinical trials.

Top 10 Value Stocks To Buy Right Now: Banco Santander, S.A.(SAN)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Whittier Trust Co. of Nevada Inc. lifted its holdings in Santander Group (NYSE:SAN) by 32.6% during the first quarter, Holdings Channel reports. The institutional investor owned 45,610 shares of the bank’s stock after buying an additional 11,224 shares during the period. Whittier Trust Co. of Nevada Inc.’s holdings in Santander Group were worth $299,000 at the end of the most recent reporting period.

  • [By Sean Williams]

    The real measure of blockchain’s game-changing potential has been the sheer number of projects and partnerships being conducted by big businesses and global organizations. For instance, the Enterprise Ethereum Alliance (EEA), the world’s largest open-source blockchain initiative, is now over 250 members. In fact, one of the EEA’s founding members, Spanish banking giant Banco Santander (NYSE:SAN), looks to be among the most willing adopters of blockchain technology within the financial sector.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Petróleo Brasileiro S.A. – Petrobras (NYSE: PBR) fell 13.2 percent to $10.95 in pre-market trading after dropping 1.33 percent on Friday.
    Banco Santander, S.A. (NYSE: SAN) shares fell 8.7 percent to $5.33 in pre-market trading after declining 2.83 percent on Friday.
    Synchrony Financial (NYSE: SYF) fell 8 percent to $32.75 in the pre-market trading session.
    AerCap Holdings N.V. (NYSE: AER) shares fell 7.4 percent to $51.17 in pre-market trading.
    Inovio Pharmaceuticals, Inc. (NASDAQ: INO) fell 7.4 percent to $4.54 in pre-market trading.
    Tailored Brands, Inc. (NYSE: TLRD) fell 7 percent to $31.83 in pre-market trading.
    California Resources Corporation (NYSE: CRC) shares fell 6.5 percent to $30.29 in pre-market trading after dropping 10.60 percent on Friday.
    Manhattan Bridge Capital, Inc. (NASDAQ: LOAN) fell 6.2 percent to $6.85 in pre-market trading.
    RedHill Biopharma Ltd. (NASDAQ: RDHL) fell 6 percent to $6.67 in pre-market trading.
    QEP Resources, Inc. (NYSE: QEP) shares fell 5.8 percent to $11.45 in pre-market trading after dropping 6.75 percent on Friday.
    Noah Holdings Limited (NYSE: NOAH) fell 5.5 percent to $61.53 in pre-market trading.
    CNH Industrial N.V. (NYSE: CNHI) shares fell 5.2 percent to $11.70 in pre-market trading

  • [By Ethan Ryder]

    Santander Group (BME:SAN) received a €5.00 ($5.81) price target from stock analysts at Citigroup in a research note issued on Tuesday. The firm presently has a “neutral” rating on the stock. Citigroup’s price objective would indicate a potential downside of 8.09% from the company’s current price.

Top 10 Value Stocks To Buy Right Now: Cal-Maine Foods, Inc.(CALM)

Advisors’ Opinion:

  • [By Shane Hupp]

    News headlines about Cal-Maine Foods (NASDAQ:CALM) have trended somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cal-Maine Foods earned a news sentiment score of 0.21 on Accern’s scale. Accern also assigned media stories about the basic materials company an impact score of 45.5279430715424 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

  • [By Logan Wallace]

    Cal-Maine Foods Inc (NASDAQ:CALM) reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $52.15 and last traded at $52.25, with a volume of 5956 shares trading hands. The stock had previously closed at $51.05.

Top 10 Value Stocks To Buy Right Now: Senior Housing Properties Trust(SNH)

Advisors’ Opinion:

  • [By Brian Feroldi, Matthew Frankel, and Dan Caplinger]

    Retirees should favor companies that operate in stable industries and offer their shareholders a predictable stream of income. So which stocks in particular do we think can fulfill their needs? We asked a team of Motley Fool investors to weigh in, and they pickedSenior Housing Properties Trust (NASDAQ:SNH),Prologis(NYSE:PLD), and 3M (NYSE:MMM).

Top 10 Value Stocks To Buy Right Now: NewMarket Corporation(NEU)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on NewMarket (NEU)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Neumark (CURRENCY:NEU) traded down 1.5% against the U.S. dollar during the one day period ending at 10:00 AM E.T. on June 8th. In the last seven days, Neumark has traded up 3.6% against the U.S. dollar. One Neumark token can now be purchased for about $0.39 or 0.00005083 BTC on popular exchanges including EtherDelta (ForkDelta), YoBit, Liqui and HitBTC. Neumark has a total market cap of $11.07 million and approximately $118,143.00 worth of Neumark was traded on exchanges in the last day.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on NewMarket (NEU)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Value Stocks To Buy Right Now: Financial Institutions Inc.(FISI)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Financial Institutions (FISI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Financial Institutions (FISI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Value Stocks To Buy Right Now: MER Telemanagement Solutions Ltd.(MTSL)

Advisors’ Opinion:

  • [By Stephan Byrd]

    News stories about MER Telemanagement Solutions (NASDAQ:MTSL) have trended somewhat positive on Sunday, according to Accern. The research group identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MER Telemanagement Solutions earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news articles about the technology company an impact score of 45.5243579518781 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Top 10 Value Stocks To Buy Right Now: Xerox Corporation(XRX)

Advisors’ Opinion:

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Natural Health Trends Corp (NASDAQ: NHTC) fell 7.8 percent to $19.80 in pre-market trading after rising 1.46 percent on Friday.
    Endocyte, Inc. (NASDAQ: ECYT) shares fell 6.6 percent to $11.41 in pre-market trading after climbing 4.18 percent on Friday.
    Quorum Health Corporation (NYSE: QHC) shares fell 6.2 percent to $5.15 in pre-market trading after tumbling 11.45 percent on Friday.
    Arcadia Biosciences, Inc. (NASDAQ: RKDA) fell 6.1 percent to $7.31 in pre-market trading after declining 3.35 percent on Friday.
    Boston Scientific Corporation (NYSE: BSX) fell 5.6 percent to $28.30 in pre-market trading.
    Evofem Biosciences, Inc. (NASDAQ: EVFM) fell 5.3 percent to $6.06 in pre-market trading after gaining 2.73 percent on Friday.
    Xerox Corporation (NYSE: XRX) shares fell 5.2 percent to $28.60 in pre-market trading. Xerox terminated its transaction agreement with Fujifilm and entered into a new agreement with Carl Icahn and Darwin Deason. JP Morgan downgraded Xerox from Overweight to Neutral.
    Cellcom Israel Ltd. (NYSE: CEL) fell 5.2 percent to $7.02 in pre-market trading. Cellcom is expected to release Q1 results on May 30, 2018.
    Perrigo Company plc (NYSE: PRGO) fell 4.5 percent to $74 in pre-market trading.
    Nabriva Therapeutics plc (NASDAQ: NBRV) shares fell 4 percent to $4.66 in pre-market trading

  • [By ]

    Here’s everything you must know before Friday’s opening bell: 

    Warren Buffett has reportedly purchased 75 million more shares of Apple (AAPL) .  Xerox (XRX) said its board & management team will remain in place after a settlement with Carl Icahn & Darwin Deason expired. Twitter (TWTR) has told all users they should change their passwords. U.S. stock futures pointed lower ahead of the U.S. jobs report. Join Jim Cramer on May 5 in New York City for an exclusive investing boot camp. Secure your spot here.

    Subscribe to our Youtube Channel for extended interviews, Cramer Replays, feature content, and more!

  • [By Douglas A. McIntyre]

    Xerox Corp. (NYSE: XRX) reversed course and said its CEO would stay after a battle thatcost him his job. According to CNBC:

    Xerox Corp said on Thursday its current board and management team, which included Chief Executive Jeff Jacobson, will stay, after a settlement agreement it had reached with dissenting shareholders to oust them expired.

  • [By Douglas A. McIntyre]

    Pressure from investors may trigger the sale of Xerox Corp. (NYSE: XRX). According to The Wall Street Journal:

    Xerox Corp.s first- and third-biggest investors, billionaires Carl Icahn and Darwin Deason, have formed an alliance and plan to encourage the printer and copier giant to explore a potential sale, according to people familiar with the matter.

Top 10 Value Stocks To Buy Right Now: Plug Power Inc.(PLUG)

Advisors’ Opinion:

  • [By Paul Ausick]

    Plug Power Inc. (NASDAQ: PLUG) saw short interest tick down 0.2% to 36.47 million shares. The number of days to cover rose from seven to eight and about 17.3% of the company’s shares were short. In the two weeks that ended May 31, the share price tumbled 12.8%. The stock’s 52-week range has been $1.53 to $3.21 and shares closed Monday at $1.93, a rise of about 2.1% for the day.

  • [By Maxx Chatsko]

    Shares of Plug Power Inc. (NASDAQ:PLUG) certainly acted that way following the release of the company’s first-quarter 2018 operating results. Year-over-year revenue growth of 91% is pretty difficult to argue with, and management thinks second-quarter 2018 sales will grow by at least 60% from the prior-year period. All in all, it’s shaping up to be a great year for top-line growth.

  • [By Maxx Chatsko]

    That much becomes clear after taking a look at fuel cell stocks Plug Power (NASDAQ:PLUG) and Ballard Power Systems (NASDAQ:BLDP). The companies generated just $235 million in revenue combined last year. While that would seem to indicate that the technology has a ways to go, a closer look shows both companies are on an upward trajectory as they position to exploit decarbonization trends. It also reveals two different growth strategies.

  • [By Peter Graham]

    A long term performance chart shows shares of FuelCell Energy severely underperforming whilesmall cap alternative energy or fuel cell stocks like Ballard Power Systems Inc (NASDAQ: BLDP), Hydrogenics Corporation (NASDAQ: HYGS) and Plug Power Inc (NASDAQ: PLUG) all peaked in 2014 with some of them showing signs of stabilization andsomepositive growth last year:

Top 5 Low Price Stocks To Buy Right Now

Citigroup’s Alastair Syme and team argue that the earnings from big oil companies like Chevron (CVX), Total (TOT) and Royal Dutch Shell (RDS.A) will be bad…real bad. But that won’t stop the stocks from outperforming. They explain why:

Bloomberg News

Negative headlines, positive performance: We expect the majority of Big Oil companies to post negative 1Q16 earnings, a brutal headline, but one that clearly reflects the impact of cyclical oil price lows this quarter. The outlook can improve. Our positive thesis on the Big Oil group reflects a belief that the market still only discounts modest oil recovery we think c. $40/bbl is imbedded in valuations and a view that the group can drive self-help gains to boost profitability even in a low price environment. Signs of this self-help should be evident in 1Q operating performance: we expect to see the delivery of top-line growth (taking market share versus broader industry) and a continued reduction in operating costs, building on substantial cost-cutting through 2015.

Top 5 Low Price Stocks To Buy Right Now: Meta Financial Group Inc.(CASH)

Advisors’ Opinion:

  • [By Shane Hupp]

    Cashcoin (CURRENCY:CASH) traded up 40.8% against the dollar during the one day period ending at 16:00 PM E.T. on May 9th. Cashcoin has a market cap of $544,583.00 and $885.00 worth of Cashcoin was traded on exchanges in the last 24 hours. Over the last seven days, Cashcoin has traded up 68.3% against the dollar. One Cashcoin coin can currently be bought for $0.0114 or 0.00000123 BTC on popular exchanges.

  • [By Ethan Ryder]

    Cash Poker Pro (CURRENCY:CASH) traded flat against the U.S. dollar during the 24 hour period ending at 19:00 PM Eastern on April 15th. Over the last week, Cash Poker Pro has traded flat against the U.S. dollar. One Cash Poker Pro token can currently be bought for approximately $0.0543 or 0.00000604 BTC on major cryptocurrency exchanges. Cash Poker Pro has a total market cap of $0.00 and approximately $0.00 worth of Cash Poker Pro was traded on exchanges in the last day.

  • [By Logan Wallace]

    COPYRIGHT VIOLATION WARNING: “$4.13 EPS Expected for Meta Financial Group Inc. (CASH) This Quarter” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at www.tickerreport.com/banking-finance/3365508/4-13-eps-expected-for-meta-financial-group-inc-cash-this-quarter.html.

Top 5 Low Price Stocks To Buy Right Now: Equity Commonwealth(EQC)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    Equity Commonwealth (NYSE:EQC) continued to steadily sell off its portfolio of real estate holdings, closing three more sales during the quarter, bringing its property count down to 13. As a result, cash flow kept declining. That trend doesn’t show any signs of ending given that the company has more properties on the market and doesn’t yet see a good opportunity to make acquisitions.

  • [By Stephan Byrd]

    HRPT Properties Trust (NYSE:EQC) had its price target boosted by investment analysts at JMP Securities to $33.00 in a report issued on Tuesday. The brokerage currently has a “market outperform” rating on the real estate investment trust’s stock. JMP Securities’ target price points to a potential upside of 4.04% from the company’s previous close.

Top 5 Low Price Stocks To Buy Right Now: Atara Biotherapeutics, Inc.(ATRA)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Atara Biotherapeutics (NASDAQ:ATRA) posted its quarterly earnings data on Tuesday. The biotechnology company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.13), MarketWatch Earnings reports.

  • [By Chris Lange]

    Atara Biotherapeutics Inc. (NASDAQ: ATRA) shares surged on Friday after the firm announced that it received clearance from the U.S. Food and Drug Administration (FDA) to initiate two Phase 3 clinical studies. Specifically these mid-stage studies deal with tabelecleucel in patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD).

  • [By Danny Vena, George Budwell, and Daniel Miller]

    With that in mind, we asked three Motley Fool contributors to identify growth stocks with intriguing potential that might not be on the radar of most investors. They pickedShopify Inc. (NYSE:SHOP), Atara Biotherapeutics, Inc. (NASDAQ:ATRA), and Criteo S.A. (NASDAQ:CRTO).

  • [By Max Byerly]

    Atara Biotherapeutics (NASDAQ:ATRA) SVP Derrell Porter sold 1,544 shares of the firm’s stock in a transaction on Tuesday, May 8th. The shares were sold at an average price of $40.15, for a total value of $61,991.60. Following the completion of the sale, the senior vice president now owns 12,500 shares in the company, valued at $501,875. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

  • [By Ethan Ryder]

    Atara Biotherapeutics (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 8,800 shares of the business’s stock in a transaction that occurred on Thursday, May 10th. The stock was sold at an average price of $39.85, for a total transaction of $350,680.00. Following the sale, the chief executive officer now owns 812,613 shares of the company’s stock, valued at $32,382,628.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Top 5 Low Price Stocks To Buy Right Now: Perceptron, Inc.(PRCP)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Perceptron (NASDAQ: PRCP) and CyberOptics (NASDAQ:CYBE) are both small-cap computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Top 5 Low Price Stocks To Buy Right Now: Ellie Mae, Inc.(ELLI)

Advisors’ Opinion:

  • [By Brian Stoffel]

    We’ll cover each of those below for these five growth stocks.

    Company What it does…
    Mercadolibre(NASDAQ:MELI) Leading e-commerce player in Latin America
    Axon Enterprises(NASDAQ:AAXN) Develops products for police forces: TASERs, body cameras, and a database to store and analyze footage
    Shopify(NYSE:SHOP) Helps merchants create an e-commerce presence
    Ellie Mae(NYSE:ELLI) Offers platform to help streamline mortgage origination and refinancing business
    Paycom Solutions(NYSE:PAYC) Maintains and develops cloud solutions for HR departments

    Chart by author.

  • [By Dan Caplinger]

    Investors are scared about the state of the mortgage market, and that’s created consternation about mortgage software platform provider Ellie Mae (NYSE:ELLI) and its ability to keep producing the huge growth that it has seen in recent years. Concerns about rising interest rates have been around for a year now, but only recently have rate increases from the Federal Reserve on the short-term end of the yield curve actually started to have a substantial upward impact on longer-term fixed mortgage rates.

Best Safest Stocks To Buy Right Now

Nordea (OTCPK:NRBAY) is, for those unfamiliar, the biggest pan-Nordic banking group, having market shares of 15-30% in each of the four Nordic countries: Denmark, Finland, Norway, and Sweden. According to Global Financial Magazine, Nordea was ranked as the 29th safest bank globally in 2017. The ranking was based on the long-term foreign currency ratings issued by Fitch Ratings, Standard & Poor’s and Moody’s Investors Service.

Source: Company data

Another indicator of its safe-haven status is the fact that Nordeas junior subordinated bonds, or the so-called CoCos, are trading at just a 3.4% yield. For comparison, JPMorgans (JPM) CoCos are trading at a 5.5% yield.

Best Safest Stocks To Buy Right Now: Plains All American Pipeline L.P.(PAA)

Advisors’ Opinion:

  • [By Dustin Parrett]

    We think Plains All American Pipeline L.P. (NYSE: PAA) is one of the best oil stocks to buy this year. In fact, we see a scenario where PAA stock could jump 20% in 2017.

  • [By Dustin Parrett]

    Plains All American Pipeline (NYSE: PAA) controls 4 million barrels of crude oil and natural gas a day.

    And with higher oil prices and fewer restrictions leading to more drilling, PAA’s pipelines will be in demand in 2017.

  • [By Matthew DiLallo]

    One of the largest projects is the Saddlehorn Pipeline, which Magellan is building with Plains All American Pipeline (NYSE:PAA) and Anadarko Petroleum (NYSE:APC). Both Plains All American Pipeline and Magellan own 40% of the project, which puts their total investment at $230 million apiece. They expect the project to be fully operational early next year, which is noteworthy given its robust first-year economics. Magellan estimates that it will earn eight times EBITDA on the capital deployed, or roughly $28.8 million in annual EBITDA apiece for Magellan and Plains All American Pipeline on their investment.

Best Safest Stocks To Buy Right Now: Digirad Corporation(DRAD)

Advisors’ Opinion:

  • [By ]

    Some of these are even smaller nano-caps, such as medical device maker Digirad (Nasdaq: DRAD), whose entire market value is just $36 million.

    There is absolutely nothing wrong with small businesses. I own shares of quite a few in my personal account. But for the most part, I use them to fill out the growth sleeve of my portfolio and don’t consider them stable income producers.

Best Safest Stocks To Buy Right Now: Regeneron Pharmaceuticals, Inc.(REGN)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Regeneron Pharmaceuticals (REGN) soared to the top of the S&P 500 today after a competitor’s competing drug failed a Phase 3 trial.

    Getty Images

    Regenerongained 3.8% to $387.10 today, while the S&P 500 declined 0.1% to 2,256.96.

    RBC’s Adnan Butt and Michael Yee offer their take:

    Two Phase 3 studies comparing Ophthotechs (OPHT) Fovista plus Lucentis to Lucentis alone did not meet the primary endpoint of demonstrating a better vision for the combination at 12 months. The improvements were 10.24 letters for the combo vs. 10.01 for Lucentis when the two Phase 3s were combined. Individually, one Phase 3 showed combo improvement of 10.74 letters vs. 9.82 letters alone and the second 9.91 letters vs. 10.36 letters with Lucentis alone. A third Phase 3 study combining Fovista with Eylea or Avastin is ongoing…

    Big overhang removed; [Regeneron] shares should be up and then continue to rise with the focus moving to dupilumab. Overhang was that Fovista success and approval could disrupt the market for Eylea as more docs tried combining nearly free Avastin (off-label) with Fovista to improve outcomes with patients. We had always argued that even under that scenario Eylea would be used since it is the most potent agent. We are buyers at current level especially ahead of the upcoming dupilumab launch.

    Regeneron’s market capitalization rose to $51.5 billion today from $39.3 billion yesterday. It reported net income of $636 million on sales of $4.1 billion in 2015.

  • [By Todd Campbell, Demitrios Kalogeropoulos, and Reuben Gregg Brewer]

    In the case of these three stocks, however, it may be worth taking a gamble. Our contributors think catalysts at Regeneron Pharmaceuticals (NASDAQ:REGN), Royal Dutch Shell (NYSE:RDS-B), and United Parcel Service (NYSE:UPS) can get them back to their winning ways. Read on to find out if these down-and-out stocks are right for your portfolio.

  • [By WWW.THESTREET.COM]

    That’s why Cramer said he’ll be listening for news coming from Celgene (CEL) , Amgen (AMGN) , Allergan (AGN) , an Action Alerts PLUS holding, and Regenron (REGN) , all of which are set to present. Of the four, Cramer said he’s sticking with Allergan and Amgen.

  • [By Chris Lange]

    Shares of Amgen Inc. (NASDAQ: AMGN) saw a handy gain to close out the week after the company won a Delaware court ruling that blocked Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) from selling their cholesterol-lowering drug in the United States. Essentially the court found that the drug Praluent actually infringed upon Amgens patents for its rival treatment Repatha.

Best Safest Stocks To Buy Right Now: Tantech Holdings Ltd.(TANH)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Friday, our Under the Radar Moversnewsletter suggestedshorting small cap China based carbon stock Tantech Holdings Ltd (NASDAQ: TANH):

    “The downtrend here is crystal clear; more of the same weakness is there on the earlier part of the chart you can’t see. What’s so compelling about the selloff is yesterday’s bar. The bulls tried to bounce back, but couldn’t… the buyers threw in the towel. TANH peeled back to close closer to the low than the high, and is following through — to the downside — today.”

Best Safest Stocks To Buy Right Now: Atara Biotherapeutics, Inc.(ATRA)

Advisors’ Opinion:

  • [By Chris Lange]

    Atara Biotherapeutics Inc. (NASDAQ: ATRA) shares surged on Friday after the firm announced that it received clearance from the U.S. Food and Drug Administration (FDA) to initiate two Phase 3 clinical studies. Specifically these mid-stage studies deal with tabelecleucel in patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD).

Best Safest Stocks To Buy Right Now: Francesca's Holdings Corporation(FRAN)

Advisors’ Opinion:

  • [By Lisa Levin] Related LOV Match Group And Spark Networks: A Valentine's Day Case Study 20 Biggest Mid-Day Losers For Thursday
    Related VKTX 15 Biggest Mid-Day Losers For Tuesday 18 Biggest Mid-Day Losers For Wednesday Companies Reporting Before The Bell
    Canadian Solar Inc. (NASDAQ: CSIQ) is expected to report its quarterly earnings at $0.32 per share on revenue of $690.27 million.
    General Mills, Inc. (NYSE: GIS) is projected to report its quarterly earnings at $0.71 per share on revenue of $3.84 billion.
    Coca-Cola European Partners Plc (NYSE: CCE) is estimated to report its quarterly earnings at $0.45 per share on revenue of $2.72 billion.
    Lands' End, Inc. (NASDAQ: LE) is expected to report its quarterly earnings at $0.35 per share on revenue of $459.43 million.
    Francesca's Holdings Corp (NASDAQ: FRAN) is estimated to report its quarterly earnings at $0.37 per share on revenue of $145.91 million.
    Cheetah Mobile Inc (ADR) (NYSE: CMCM) is projected to report its quarterly earnings at $0.06 per share on revenue of $178.04 million.
    Neogen Corporation (NASDAQ: NEOG) is estimated to report its quarterly earnings at $0.27 per share on revenue of $90.05 million.
    Lennar Corporation (NYSE: LEN) is projected to post earnings for its first quarter.
    Fifth Street Asset Management Inc (NASDAQ: FSAM) is expected to report its quarterly earnings at $0.14 per share on revenue of $25.12 million.

     

  • [By Lisa Levin]

    Francesca's Holdings Corporation (NASDAQ: FRAN) was down, falling around 9 percent to $7.09 following downbeat quarterly earnings.

    Commodities

  • [By Paul Ausick]

    Francesca’s Holdings Corp. (NASDAQ: FRAN) dropped about 4.5% Monday to post a 52-week low of $5.68 after closing at $5.95 on Friday. The 52-week high is $19.50. Volume was around 2.7 million, more than double the daily average. The specialty retailer lowered its fourth-quarter outlook last Friday and the investor walkaway continues.

  • [By Ben Levisohn]

    Francesca’s Holdings (FRAN) has jumped 5.4% to $11.00 after beating earnings forecasts.

    Restoration Hardware (RH) has tumbled 20% to $28.92 after slashing its full-year guidance. Restoration Hardware was also cut to Market Perform from Outperform at Telsey Advisory Group.

Top 10 Performing Stocks To Buy For 2018

March 16, 2017: Markets opened higher again Thursday but the uptick did not last longer. Within an hour shares had dropped and a brief turn higher was foiled quickly. The worst performing sectors for the day are utilities and healthcare, with financials showing the only decent gain. WTI crude oil for April delivery settled at $48.75 a barrel, down 0.2% on the day. April gold added 2.2% on the day to settle at $1,227.10. Equities were headed for a lower close shortly before the bell as the DJIA traded down 0.11% for the day, the S&P 500 traded down 0.22%, and the Nasdaq Composite traded down 0.02%.

The DJIA stock posting the largest daily percentage loss ahead of the close Thursday was E.I. du Pont de Nemours Inc. (NYSE: DD) which traded down 1.14% at $80.56. The stock’s 52-week range is $61.12 to $81.51. Volume was roughly 40% below the daily average of around 2.6 million shares. The company had no specific news.

Chevron Corp. (NYSE: CVX) traded down 1.00% at $107.79. The stock’s 52-week range is $92.25 to $119.00. Volume was about 10% below the daily average of around 6.3 million shares. The integrated oil & gas company had no specific news.

Top 10 Performing Stocks To Buy For 2018: Tobira Therapeutics, Inc.(TBRA)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    Allergan (NYSE: AGN) acquired Akarna Therapeutics global rights to AKN-083 for up-front payment of $50 million. This came just hours after Allergan bought Tobira Therapeutics (NASDAQ: TBRA) for upfront Payment of $28.35 share in cash, up to $49.84 per share in CVRs.

Top 10 Performing Stocks To Buy For 2018: TESARO, Inc.(TSRO)

Advisors’ Opinion:

  • [By George Budwell]

    Unfortunately for Clovis and its shareholders, though, Astra’s Lynparza is currently underpriority review with the FDA as a maintenance therapy in ovarian cancer, andTesaro’s (NASDAQ:TSRO)rival PARP inhibitor Zejula gained an early approval– along with afar broader label than Rubraca — just this week.

  • [By Ben Levisohn]

    Who has PARP? A poly ADP-ribose polymerase inhibitor (PARPi) kills cancer cells by interfering tumor DNA repair pathway with the potential to treat ovarian, breast and prostate cancer. Studies have shown that patients with BRCA mutations (BRCAmut) respond to PARPi. AstraZenecas (AZN) PARPi was approved in 2014 whileClovis Oncology (CLVS) and Tesaro (TSRO) both have positive Phase III data. Clovis licensed its PARPi from Pfizer (PFE) in 2011 and Tesaro licensed its PARPi from Merck (MRK) in 2012, after Sanofis (SNY) PARPi (later demonstrated that it cannot block PARP) failed in Phase III in early 2011.

  • [By Todd Campbell]

    The PARP battle is on. Following news that AstraZeneca’s (NYSE:AZN) PARP-inhibiting cancer drug Lynparza delivered a big win in phase 3 studies, all eyes now shift to how a potential Food and Drug Administration approval for Lynparza will reshape the commercial opportunity for competitor Tesaro Inc. (NASDAQ:TSRO).

  • [By Ben Levisohn]

    Shares of Tesaro (TSRO) are soaring today after the biotech company reported positive data for its treatment of ovarian cancer over the weekend. Credit Suisse analyst Alethia Young and team contend that “M&A remains in focus” for Tesaro following the data:

    Getty Images

    We are increasing our target price to $122 from $90 as we move to an M&A DCF valuation. We were at ESMO this weekend, and we believe the big takeaway on Tesaro data is that it works broadly in all 2L ovarian populations and safety looks solid. We also think the robustness of this data bodes well from PRIMA and QUADRA but are maintaining our POS here. We have looked at our model and also adjusted durations in first-line. We think Tesaro remains one of the most attractive and de-risked cancer assets in our landscape and the company has been cited in major press sources as a takeout target (Bloomberg, Investor Business Daily).

    We think M&A remains in focus for Tesaro. Our M&A DCF valuations range from $122 to $157 by our model. We have also built models for other cancers like NSCLC, SCLC, prostate, and others where PARP might be impactful. We assume 0% POS for now but we conservatively see at least another $1B in sales from PARP expansion. Tesaro has been cited in the press as a potential M&A target and is a company we frequently hear mentioned as a target from our conversations. We think the demand for late stage oncology assets is high, especially in the PARP space given the potential for activity across a range of tumors. For a large Pharma player who already has an oncology salesforce and large R&D infrastructure we could see SG&A synergies of 50-75% and R&D synergies of 15-30%. In our base case TSRO P&L we model a tax rate of 30% so there could be synergies here as well. Two additional key swing factors which might be included in a CVR are how much expansion from PARP in other cancers and immuno-oncology…

    Ex M&A,

  • [By Ben Levisohn]

    Look out below! Shares of Tesaro (TSRO) have dropped more than 10% this afternoon after AstraZeneca (AZN) released stronger-than-expected Phase 3 trial data on a its ovarian cancer treatment.

    Agence France-Presse/Getty Images

    The Street’sAdam Feuerstein has the details on AstraZeneca’s strong data and its impact on Tesaro:

    AstraZeneca’s (AZN) PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo, according to results from a phase III study presented Tuesday.

    The strong benefit observed with Lynparza as ovarian cancer maintenance therapy exceeded investor expectations and bolsters AstraZeneca against a competing PARP inhibitor from Tesaro (TSRO).

    Feuerstein also notes that AstraZeneca’s data could be good newsClovis Oncology (CLVS), which also had a PARP inhibitor approved recently, if it means that its drug could work as well as Astra’s.

    In February, Leerink cut Tesaro, arguing that the rally in its shares due to a potential takeover had run too far. Will it still be a takeover target?

    Shares of Tesaro have dropped 14% to $148.01 at 3:28 p.m. today, while AstraZeneca has gained 1.1% to $30.41, and Clovis Oncology has jumped 9.8% to$66.55.

    UPDATE:Piper Jaffray’sSteven Breazzano andJoshua Schimmer note that the AstraZeneca data shows that PARPs are “more similar than different.” They explain:

    This afternoon AstraZeneca (covered by PJC analyst Richard Purkiss) reported the detailed results from the SOLO-2 maintenance study of Lynparza in 2L+ ovarian cancer. The detailed data highlights a PFS benefit of 14 months (investigator assessed, and primary endpoint) and 25 months (blinded central review) over placebo, and favorable hazard ratio of 0.30 and 0.25, respectively, confirming our view that the PARP’s are more similar than different. As such, we believe this provides a favorable readth

Top 10 Performing Stocks To Buy For 2018: Cardiome Pharma Corporation(CRME)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of CARDIOME PHARMA CORP (NASDAQ: CRME) were down 30 percent to $2.72 after the company issued U.S. regulatory update for BRINAVESS. The FDA advised Cardiome that the data package proposed is not sufficient to support re-submission of the BRINAVESS NDA.

  • [By Lisa Levin]

    Shares of CARDIOME PHARMA CORP (NASDAQ: CRME) were down 43 percent to $3.01. Cardiome priced 10 million shares at $3 per share.

    Seadrill Partners LLC (NYSE: SDLP) was down, falling around 30 percent to $4.09 as the company announced plans to reduce the quarterly cash distribution to $0.10 per unit from $0.25 per unit.

Top 10 Performing Stocks To Buy For 2018: Blackrock Global(BOE)

Advisors’ Opinion:

  • [By Robert Rapier]

    Whiting Petroleum (WLL) is one of Continental’s biggest competitors in the Bakken. Whiting is the second-largest oil producer in North Dakota, averaging 82,500 barrels of oil equivalent (BOE) of production in 2012, across more than 700,000 acres of leased land.

Top 10 Performing Stocks To Buy For 2018: Atara Biotherapeutics, Inc.(ATRA)

Advisors’ Opinion:

  • [By Chris Lange]

    Atara Biotherapeutics Inc. (NASDAQ: ATRA) shares surged on Friday after the firm announced that it received clearance from the U.S. Food and Drug Administration (FDA) to initiate two Phase 3 clinical studies. Specifically these mid-stage studies deal with tabelecleucel in patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD).

Top 10 Performing Stocks To Buy For 2018: Clarke(t)

Advisors’ Opinion:

  • [By Jim Robertson]

    DirecTV is a direct broadcast satellite service provider and is a subsidiary of AT&T Inc (NYSE: T). Its satellite service, launched on June 17, 1994, transmits digital satellite television and audio to households in the United States, Latin America and the Caribbean withprimary competitorsbeing Dish Network and cable television providers. On July 24, 2015, after receiving approval from the FCC and United States Department of Justice, AT&T acquired DirecTV in a transaction valued at $48.5 billion. DirecTV would be paying$1.5 billion a year for the NFL Sunday Ticket.AT&T’s shares may have broken out of a downtrend:

  • [By Brian Feroldi, Dan Caplinger, Rich Duprey, Jason Hall, and Jordan Wathen]

    In order to point you in the right direction, we asked a team of Fools to highlight a dividend stock that they feel is a great stock for a beginner. Read on to see why they picked AT&T (NYSE:T),Apple (NASDAQ:AAPL),Anheuser-Busch InBev(NYSE:BUD), Mastercard(NYSE:MA), andJPMorgan Chase(NYSE:JPM).

  • [By Paul Ausick]

    AT&T Inc. (NYSE: T) dropped about 1.4% Tuesday to post a new 52-week low of $35.87 after closing Monday at $36.39. The 52-week high is $43.50. Volume was around 5.8 million shares traded, nearly 10 times the daily average of around 600,000. The company had no specific news.

  • [By Douglas A. McIntyre]

    At the other end of the iPhone 8 spectrum, wireless companies like AT&T Inc. (NYSE: T) probably will price the low-end version of the iPhone 8 below $40 a month, with 24-month contracts. This kind of price plan is a usual way for large wireless carriers to get and hold customers for long periods. Even if the carrier pays a lot for the smartphone, it presumably makes that back in monthly fees and on people who renew their subscriptions for a longer period.

  • [By Chris Lange]

    AT&T Inc.’s (NYSE: T) second-quarter results are scheduled for Tuesday. The consensus earnings estimate is $0.74 per share, on $39.82 billion in revenue. The shares were last seen at $36.51. The consensus price target is $40.27, and the 52-week trading range is $35.81 to $43.50.

Top 10 Performing Stocks To Buy For 2018: Snap-On Incorporated(SNA)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Coming up on this episode of Mad Money: Cramer interviews Nick Pinchuk, CEO of Snap-on (SNA) . Plus, don’t miss the Lightning Round. Which stocks is Cramer bullish on?

  • [By John Divine]

    Snap-on Incorporated (SNA) is my choice for the Best Stocks for 2016 competition. At a market cap of $10 billion, I doubt it will double over the next year, as some of the smaller companies in this competition might be able to.

    That said, Snap-on, which manufactures and markets hand tools and diagnostic equipment, is a rock-solid company with an attractive valuation and impressive growth. It goes for 22 times earnings, pays a consistent and modest dividend, and has been around since 1920.

    As cars get more tech-heavy and complicated, newer tools and better diagnostics will be needed — and that’s SNA’s bread ‘n’ butter. 

  • [By WWW.MONEYSHOW.COM]

    Snap-on (SNA)

    Snap-on, which is more than 100 years old, provides hand and power tools for individuals and professionals, including auto-shop tools and auto diagnostic equipment.

Top 10 Performing Stocks To Buy For 2018: PRA Group, Inc.(PRAA)

Advisors’ Opinion:

  • [By Lee Jackson]

    PRA Group Inc. (NASDAQ: PRAA) has been hit hard recently, and shareholders may be glad to know that a director took advantage of the sell-off and stepped in to buy shares. That board member bought 143,000 shares of the financial and business services company at prices that ranged from $34.40 to $34.89. The total for the buy was set at $5 million. The stock closed Friday at $32.90, in a52-week range of $21.93 to $42.70. The consensus price target is $40.60.

Top 10 Performing Stocks To Buy For 2018: Tyson Foods Inc.(TSN)

Advisors’ Opinion:

  • [By Lisa Levin] Companies Reporting Before The Bell
    Tyson Foods, Inc. (NYSE: TSN) is expected to report quarterly earnings at $1.38 per share on revenue of $9.86 billion.
    Aecom (NYSE: ACM) is projected to report quarterly earnings at $0.71 per share on revenue of $4.67 billion.
    JD.Com Inc(ADR) (NASDAQ: JD) is estimated to report quarterly earnings at $0.11 per share on revenue of $12.60 billion.
    58.com Inc (ADR) (NYSE: WUBA) is projected to report quarterly earnings at $0.28 per share on revenue of $383.60 million.
    Kamada Ltd (NASDAQ: KMDA) is expected to report quarterly earnings at $0.02 per share on revenue of $25.00 million.
    Palatin Technologies, Inc. (NYSE: PTN) is projected to report quarterly earnings at $0.06 per share on revenue of $28.00 million.
    TheStreet, Inc. (NASDAQ: TST) is estimated to report a quarterly loss at $0.02 per share on revenue of $15.81 million.
    Atlantica Yield PLC (NASDAQ: ABY) is projected to report quarterly earnings at $0.45 per share on revenue of $290.80 million.
    Asure Software Inc (NASDAQ: ASUR) is estimated to report quarterly earnings at $0.15 per share on revenue of $15.26 million.
    Cyren Ltd (NASDAQ: CYRN) is expected to report quarterly loss at $0.06 per share on revenue of $7.90 million.
    Viewray Inc (NASDAQ: VRAY) is estimated to report quarterly loss at $0.12 per share on revenue of $18.58 million.

     

  • [By Peter Graham]

    A long term performance chart shows shares ofmid cap Sanderson Farms more than doubling in value while large cap Tyson Foods, Inc (NYSE: TSN)has more than tripled in value and mid cap Pilgrim’s Pride Corporation (NASDAQ: PPC) has quadrupled in value:

  • [By Peter Graham]

    A long term performance chart shows shares of small cap Sanderson Farms doubling in value while mid cap Pilgrim’s Pride Corporation (NASDAQ: PPC) and large cap Tyson Foods, Inc (NYSE: TSN) have been even better performers albeit shares are below their peaks and have been somewhat volatile:

Top 10 Performing Stocks To Buy For 2018: Oasis Petroleum Inc.(OAS)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Oasis Petroleum Inc. (NYSE: OAS) were down 14 percent to $8.60 after the company reported a 32 million share common stock offering. The company announced Delaware Basin acquisition for $946 million and also raised its Q4 production guidance.

  • [By Jon C. Ogg]

    Oasis Petroleum Inc. (NYSE: OAS) rose a whopping 27.8% to $14.98, and the 33.2 million shares was about 2.5 times normal volume. Oasis Petroleum has a 52-week trading range of $3.40 to $15.02 and a consensus analyst price target of $14.54. The company has a total market cap of $3.5 billion.

  • [By Chris Lange]

    Oasis Petroleum Inc. (NYSE: OAS) shares slid on Tuesday after the company announced that it would be buying into the Delaware Basin. Analysts seemed to applaud this move, despite investors sending shares into the fire. Jefferies raised its price target to $14 from $13, and Morgan Stanley raised its target to $11 from $9. RBC has an Outperform rating and raised its target to $14 from $13, while SunTrust Robinson Humphrey downgraded it to Hold from Buy. Shares were down about 14% at $8.67, in a 52-week range of $6.69 to $16.73.

  • [By Paul Ausick]

    Oasis Petroleum Inc. (NYSE: OAS) is rated a Buy and the price target was lifted to $24. For 2017, the net loss estimate improved from a prior $0.27 per share to $0.23 per share. The 2018 EPS estimate rose from $0.62 to $0.64. Shares closed at $14.13 on Friday. The 52-week range is $5.93 to $14.35, and the consensus 12-month target is $17.87.

  • [By Craig Jones]

    Jon Najarian spoke on CNBC’s “Fast Money Halftime Report” about unusually high options activity in Oasis Petroleum Inc. (NYSE: OAS).

    Traders bought around 10,000 contracts of the June 10 calls in the first half of the trading session on Thursday. The trade is unusual because the average options volume in the name is a few hundred contracts. Najarian bought the calls and is planning to hold them for two weeks.

us stock market holidays

Free Preview

For full access, Log in or Subscribe Now and get 4 weeks free!

First, the definition: RMD stands for Required Minimum Distribution from a qualified retirement plan. When you contributed to an IRA you received a tax deduction. Contributions to a 401(k), 403 (b), or 457 went into the account before taxes were assessed (a pre-tax contribution). All of these plans are agreements between three parties:

us stock market holidays: BioAmber Inc.(BIOA)

Advisors’ Opinion:

  • [By Lisa Levin] Related CRMD Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher 12 Biggest Mid-Day Gainers For Tuesday CorMedix's (CRMD) CEO Khoso Baluch on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    Related BIOA Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates BioAmber (BIOA) Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    CorMedix Inc. (NYSE: CRMD) shares fell 27.5 percent to $1.50 after the company reported Q4 results and issued a business update.
    Bioamber Inc (NYSE: BIOA) shares tumbled 23.6 percent to $2.40. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million.
    The Medicines Company (NASDAQ: MDCO) shares dipped 20.9 percent to $41.62.
    Innocoll Holdings PLC (NASDAQ: INNL) shares fell 20.3 percent to $1.49. Innocoll posted a narrower-than-expected quarter loss, but revenue missed estimates. Stifel Nicolaus downgraded Innocoll from Buy to Hold.
    Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares declined 20.3 percent to $3.83. On Thursday, Rosetta Genomics disclosed a 1-for-12 reverse stock split.
    Esperion Therapeutics Inc (NASDAQ: ESPR) shares dropped 19.9 percent to $23.76. Esperion Therapeutics shares have jumped 106.19 percent over the past 52 weeks, while the S&P 500 index has gained 16.70 percent in the same period.
    AmTrust Financial Services Inc (NASDAQ: AFSI) tumbled 18.3 percent to $17.65. AmTrust Financial disclosed that it will delay its annual report filing for the fiscal year ended December 31, 2016.
    Qualstar Corporation (NASDAQ: QBAK) slipped 17.7 percent to $6.85. Qualstar reported a Q4 loss of $0.20 per share on revenue of $2.2 milli
  • [By Lisa Levin]

    Bioamber Inc (NYSE: BIOA) shares dropped 19 percent to $2.55. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million.

  • [By Paul Ausick]

    BioAmber Inc. (NYSE: BIOA) dropped nearly 29% Friday to post a new 52-week low of $2.24 after closing Thursday at $3.14. Volume of more than 1.5 million shares was about 6 times the daily average of around 240,000. The company’s annual report, filed on Thursday with its quarterly results, included a “going concern” statement from the company’s independent auditing firm.

us stock market holidays: Clean Diesel Technologies Inc.(CDTI)

Advisors’ Opinion:

  • [By Monica Gerson]

    Clean Diesel Technologies, Inc. (NASDAQ: CDTI) is projected to post a quarterly loss at $0.18 per share on revenue of $10.25 million.

    Sphere 3D Corp. (NASDAQ: ANY) is estimated to post a quarterly loss at $0.11 per share on revenue of $22.10 million.

us stock market holidays: Sears Holdings Corporation(SHLD)

Advisors’ Opinion:

  • [By Lee Jackson]

    Troubled Sears Holdings Corp. (NASDAQ: SHLD) again saw some insider buying. Fairholme Capital, a 10% owner, bought shares twice. One buy late in the week was 613,900 shares of the iconic retailer at prices that ranged from $7.89 to $9.00 apiece. The total for the trade was posted at $5 million. Earlier in the week, Fairholme bought 222,100 shares at prices between $8.75 and $8.86 a share. The total for that buy was set at $2 million. The stock closed Friday at $8.50. Its 52-week trading range is $5.50 to $19.12, and the Wall Street consensus price target is just $4.00.

  • [By Dan Caplinger]

    Yet some solid individual stock gains also helped lift investors’ moods, and Sears Holdings (NASDAQ:SHLD), National Beverage (NASDAQ:FIZZ), and JetBlue Airways (NASDAQ:JBLU) were among the best performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so well.

  • [By Ben Levisohn]

    Sears Holdings (SHLD) reported earnings today, but don’t let its 6%-plus gain fool you. Sears is still “highly distressed,” at least according to one analyst.

    Getty Images

    Sears reported a $1.28 per share loss during the fourth quarter, smaller than the $1.70 it lost a year ago, though sales dropped to $6.05 billion, down from $7.3 billion. Cowen’s Oliver Chen and team call Sears “highly distressed.” They explain:

    Overall, SHLD remains highly distressed with significant cash constraints and will continue to close a significant number of stores and will likely continue to sell other assets to stabilize the business. We believe this presents an opportunity for other department stores and broadline retailers to continue gaining share at SHLD’s expense.

    Sears’ pain could be particularly helpful for JC Penney (JCP), Chen says:

    In our view, weakness at Sears in the home appliances and tools categories providesJC Penney an opportunity to gain share as the retailer continues to refresh its home initiatives. Recall,JC Penney already delivered positive comps in the Home division in 4Q and management is very pleased with performance with ~500 appliance showrooms which have been driving sales and gross margin dollars. We believeJC Penney has ample runway to continue driving strong performance in this department with plans to open an additional ~100 new appliance showrooms in early 2017, while continuing to add new brand partners. Furthermore, with Sears donating share,JC Penney management plans to conduct several tests within their Home Store with a focus on its home installed services program. For example,JC Penney will test an HVAC install program through its partnership with Trane and other partners.

    Shares of Sears have gained 6.1% to $7.95 at 2:23 p.m. today, while JC Penney is unchanged at $6.24.

  • [By Daniel Miller]

    It seems like Sears Holdings (NASDAQ:SHLD) has been on its death bed for some time now, and it tumbled another 20% this week setting new lows since Sears and Kmart merged roughly a decade ago. The issue facing investors this week appeared to be Sears’ liquidity. Credit-rating agency Fitch Ratings kept its speculative CC rating on the company, which suggests that a debt default is increasingly likely.

  • [By WWW.THESTREET.COM]

    Best Buy certainly has not seen the same destruction to its business like other retailers, mainly in the apparel space, have from Amazon, including Sears Holdings Corp. (SHLD) and J.C. Penney Co. Inc. (JCP) . While Best Buy’s revenue growth has been weak over the past several years, it has managed to consistently beat Wall Street profit forecasts via a combination of cost cuts and stock buybacks.

  • [By Paul Ausick]

    Sears Holdings Corp. (NASDAQ: SHLD).Between Sears and Kmart stores, the company plans 142 store closings, with more likely.

    Sports Authority.Another bankruptcy, with 140 stores closing.

us stock market holidays: PPL Corporation(PPL)

Advisors’ Opinion:

  • [By Paul Ausick]

    PPL Corp. (NYSE: PPL) posted a 52-week low of $30.81 after closing Friday at $31.13. The 52-week high is $40.20. Volume was about 3.5 million, about 25% below the daily average of around 4.5 million shares. The electric utility company had no specific news.

  • [By Paul Ausick]

    PPL Corp. (NYSE: PPL) dropped about 1.7% Tuesday to post a new 52-week low of $30.44 after closing at $30.95 on Friday. Volume was around 4.1 million about 10% below the daily average of around 4.6 million. The company had no specific news.

  • [By Paul Ausick]

    PPL Corp. (NYSE: PPL) posted a 52-week low of $32.48 after closing Monday at $33.97. The 52-week high is $40.20. Volume was about 5.9 million, nearly a third higher than the daily average of around 3.9 million shares. The electric utility company had no specific news.

  • [By Paul Ausick]

    PPL Corp. (NYSE: PPL) posted a 52-week low of $30.74 after closing Tuesday at $30.76. The 52-week high is $40.20. Volume was about 3.2 million, about 25% below the daily average of around 4.5 million shares. The electric utility company had no specific news.

  • [By Paul Ausick]

    PPL Corp. (NYSE: PPL) posted a 52-week low of $31.11 after closing Wednesday at $31.59. The 52-week high is $40.20. Volume was about 9.6 million, more than double the daily average of around 4.2 million shares. The electric utility company had no specific news.

  • [By Paul Ausick]

    PPL Corp. (NYSE: PPL) posted a 52-week low of $31.53 after closing Tuesday at $32.42. The 52-week high is $40.20. Volume was about 15.5 million, more than three times the daily average of around 4 million shares. The electric utility company took a downgrade on Tuesday and the fallout continues to drop.

us stock market holidays: Atara Biotherapeutics, Inc.(ATRA)

Advisors’ Opinion:

  • [By Chris Lange]

    Atara Biotherapeutics Inc. (NASDAQ: ATRA) shares surged on Friday after the firm announced that it received clearance from the U.S. Food and Drug Administration (FDA) to initiate two Phase 3 clinical studies. Specifically these mid-stage studies deal with tabelecleucel in patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD).